Nasdaq · Healthcare
Astrana Health, Inc. (ASTH)
As-reported financials and recent SEC filings for Astrana Health, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.18B
Net income
$22.5M
Net margin
0.7%
Diluted EPS
$0.46
ROE
2.8%
P/E (TTM)
73.0×
Market cap
$2.21B
Debt / equity
1.2×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.03B | $1.39B | $1.14B | $773.9M |
| Gross profit | — | — | — | — | $177.8M |
| Operating income | $78.5M | $89.3M | $84.6M | $104.3M | $98.2M |
| Net income | $22.5M | $43.1M | $60.7M | $45.2M | $68.9M |
| Diluted EPS | $0.46 | $0.90 | $1.29 | $0.99 | $1.52 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →S-82026-06-11
View on EDGAR →8-K2026-06-10
View on EDGAR →Go deeper on ASTH
Search Astrana Health, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.